Abstract 17773: Baseline Cardiovascular Disease, Risk Factors, and Subsequent Changes Among Newly Diagnosed Prostate Cancer Patients
Background: Currently there are 3 million prostate cancer (PCa) survivors in the US with roughly 500,000 receiving androgen-deprivation therapy (ADT), a mainstay of treatment. As cancer survival continues to improve, focus shifts to treatment-related morbidity and non-cancer mortality of which cardiovascular disease (CVD) is most common. Although an FDA safety label was added to ADT in 2010 recommending management of traditional cardiovascular (CV) risk factors due to a possible increase in CVD and diabetes, little is known regarding baseline and subsequent changes in all newly diagnosed prostate cancer patients.
Methods: The Synthetic Derivative at Vanderbilt University Medical Center, a database of over 2.5 million de-identified patient records, was used to identify prevalence of baseline CVD (CAD, heart failure, stroke) and CV risk factors (hypertension, dyslipidemia, diabetes mellitus, body mass index (BMI), smoking status), and linked to the Vanderbilt Tumor Registry to identify all newly diagnosed prostate cancer patients divided by treatment type (prostatectomy alone, ADT alone, both, or neither). CV risk factor and CVD incidence by therapy were calculated at 1 year.
Results: We studied 9814 prostate cancer patients (median age 61 for prostatectomy only and 68 for ADT only; median cancer TNM Stage: 2). CVD and CV risk factors were most common in the ADT only group (HTN 43%, dyslipidemia 26.6%, diabetes mellitus 11.5%, CAD 14.3%, heart failure 2.3%, stroke 2.2%). Only ~10% had a documented smoking status, BMI, or lipid panel. Table 1 shows the incidence of CVD and CV risk factors at 1 year.
Conclusion: There is a higher prevalence of baseline CVD and CV risk factors among PCa patients receiving ADT therapy. CV screening remains low. Within the first year, the incidence of CVD and CV risk factors continues to rise among all PCa treatment groups highlighting the importance of early screening and aggressive management of traditional CV risk factors.
Author Disclosures: J. Singh: None. N. Bhatia: None. E. Farber-Eger: None. Q. Wells: None. J. Moslehi: None.
- © 2016 by American Heart Association, Inc.